Highlands Acquisition Corporation (AMEX: HIA), a special purpose acquisition company, is organized to acquire one or more operating businesses. Highlands seek all attractive business opportunities with the potential for significant returns. The New Jersey Company is led by their CEO Bob Pangia who has a wealth of experience in the healthcare industry. For further information, visit the company website at: www.highlandscorp.com.
HemoBioTech, Inc. (OTC BB: HMBT), a biopharmaceutical company, is focused on developing HemoTech™, which may be the first viable substitute for human blood. HemoTech™, the company’s core product, is a bovine-hemoglobin (Hb) based human blood substitute that has the capability of replacing red blood cells in the human body. The company has an exclusive worldwide license for HemoTech, and intends to use its technology to meet the increasing demand for safe and inexpensive human blood substitute product around the world. For further information, visit the Company's web site at www.hemobiotech.com.
Hana Biosciences, Inc. (NASDAQ: HNAB), a South San Francisco, CA-based biopharmaceutical company, is focused on the acquisition, development and commercialization of novel products to strengthen the foundation of cancer care. The company is dedicated to creating value by accelerating the development of lead product candidates, building a best-in-class team, expanding its pipeline, and nurturing a unique company culture. For further information, visit the Company's web site at www.hanabiosciences.com.
Gulf Resources (OTC BB: GFRE) is a leading provider of bromine, crude salt and a portfolio of various specialty chemicals throughout China. Gulf is one of only six companies with a highly coveted Chinese license for bromine exploration, production and distribution. Gulf also develops for Chinese paper making and oil and gas industries. The company is looking to expand by pursuing complimentary acquisitions. This, coupled with organic growth, makes Gulf Resources a company to keep an eye on. For further information, visit the company website at: www.gulfresources.com.
GTx, Inc. (NASDAQ: GTXI) is a biopharmaceutical company focused on the discovery, development, and commercialization of small molecules to treat cancer, osteoporosis and bone loss, muscle wasting, and other serious medical conditions. The company’s product candidate in clinical development, ACAPODENE, is a selective estrogen receptor modulator that is in pivotal Phase III clinical trials for the treatment of multiple serious side effects of androgen deprivation therapy for advanced prostate cancer. For further information, visit the Company's web site at www.gtxinc.com.
GTC Biotherapeutics, Inc. (NASDAQ: GTCB) is focused on developing, supplying, and commercializing therapeutic proteins created through transgenic animal technology. ATryn, the company’s recombinant human antithrombin, has received approval for use in Europe and is in the review process in the United States under a rolling Biologics License Application. The company’s intellectual property includes a patent in the United States for the production of therapeutic proteins in the milk of transgenic mammals. For further information, visit the Company's web site at www.gtc-bio.com.
Grey Wolf Exploration Inc. (TSX: GWE CN), an independent, Alberta-based, junior energy company, is focused on the development and production of natural gas and crude oil in the Western Canadian Sedimentary Basin. The company aims to redevelop under-exploited properties through the use of inhouse expertise, current technologies such as 3D seismic, and prudent business practices. Grey Wolf’s internally-generated portfolio of drilling opportunities also includes complementary exploration projects. For further information, visit the Company's web site at www.greywolf.ca.
Great Panther Resources Limited (TSX: GPR CN), one of the fastest growing primary silver producers in Mexico, owns 100% interest in two operating mines and two high quality exploration projects and employs almost 600 people. The company is devoted to conducting all operations with fairness and integrity while maintaining cost-effective efforts. With strong, experienced local management and infrastructure, Great Panther’s primary aim is to generate positive cash flow through the advancing of production rates. For further information, visit the Company's web site at www.greatpanther.com.
Gran Tierra Energy Inc. (TSX: GTE CN), an international oil and gas exploration and production company, holds interests in producing and prospective properties in Colombia, Argentina and Peru. The Company aims to establish a portfolio of drilling opportunities to exploit undeveloped reserves to grow production, as well as undertake exploration drilling to grow future reserves. Grey Wolf has a working interest in nineteen different blocks that cover approximately 6.5 million acres. For further information, visit the Company's web site at www.grantierra.com.
Golden Pond Healthcare, Inc. (AMEX: GPH) is a company focused on making investments in the Healthcare industry. The principals of Golden Pond have extensive experience in various sectors of healthcare, including managed care and disease management; healthcare services; pharmaceuticals and specialty pharmaceuticals; and medical devices. Golden Pond was organized as special purpose acquisition corporation (SPAC) which gives it great leverage. For further information, visit the company website at: www.goldenpondhealthcare.com.
